A组轮状病毒VP6与霍乱毒素B亚基融合蛋白在大肠杆菌中的表达及生物活性分析

利用霍乱毒素B亚基 (CholeratoxinBsubunit,CTB)的免疫载体作用 ,将轮状病毒相关抗原引入口服免疫体系 ,可激起有效的粘膜免疫反应 ,这里报道了CTB基因与A组轮状病毒地方株T114VP6全基因的融合 ,并在大肠杆菌BL21(DE3 )中进行了融合蛋白的表达。在IPTG诱导下得到分子量为 5 6kD的融合蛋白 ,表达量占菌体蛋白的15 %。分别用抗CT的抗体和抗A组轮状病毒的高价免疫血清进行WesternBlot检测 ,结果证明融合蛋白CTB VP6保留了天然霍乱毒素B亚基及轮状病毒VP6的抗原性。G_M1-ELISA检测表明 ,复性后的融合蛋白具有与神经节苷脂GM1 结合的能力。     

HPV16重组减毒沙门氏菌表达质粒的构建及其诱导免疫

将人乳头瘤病毒(Human papillomavirus,HPV)16 L1E7基因插入携带霍乱毒素基因的pET-CTA2B载体,获得HPV16L1E7与CTA2B融合表达质粒pET-L1E7CTA2B.在此基础上,通过PCR基因克隆技术,将pET载体的T7启动子与pTETnir15载体的大肠杆菌硝酸盐还原酶基因B启动子nirB进行分割重组,将nirB启动子的厌氧调控元件和启动子基本元件FNR-TATA盒与T7启动子的核糖体结合位点(SD)序列融合,形成nirB-T7杂合启动子.最后获得HPV16重组减毒沙门氏细菌疫苗表达载体pNir-16L1E7CTA2B,并进一步构建对照质粒pNir-16L1E7.Western blot结果证实以上质粒nirB-T7杂合启动子能够在沙门氏细菌中表达L1E7融合蛋白.口服免疫接种小鼠可成功诱导小鼠生殖道产生HPV16特异性粘膜免疫,且霍乱毒素CTA2B可以增强粘膜免疫诱导能力,为开发廉价有效的HPV16预防性疫苗打下了基础.     

HPV16重组减毒沙门氏菌表达质粒的构建及其诱导免疫

将人乳头瘤病毒(Human papillomavirus,HPV)16 L1E7基因插入携带霍乱毒素基因的pET CTA2B载体,获得HPV16L1E7与CTA2B融合表达质粒pET L1E7CTA2B。在此基础上,通过PCR基因克隆技术,将pET载体的T7启动子与pTETnir15载体的大肠杆菌硝酸盐还原酶基因B启动子nirB进行分割重组,将nirB启动子的厌氧调控元件和启动子基本元件FNR TATA盒与T7 启动子的核糖体结合位点(SD)序列融合,形成nirB T7 杂合启动子。最后获得HPV16重组减毒沙门氏细菌疫苗表达载体pNir 16L1E7CTA2B,并进一步构建对照质粒pNir 16L1E7。Western blot结果证实以上质粒nirB T7杂合启动子能够在沙门氏细菌中表达L1E7 融合蛋白。口服免疫接种小鼠可成功诱导小鼠生殖道产生HPV16 特异性粘膜免疫,且霍乱毒素CTA2B可以增强粘膜免疫诱导能力,为开发廉价有效的HPV16预防性疫苗打下了基础。     

阿拉伯启动子控制的霍乱毒素B亚单位基因在大肠杆菌中的表达

霍乱毒素B亚单位是预防霍乱重要的保护性抗原,由霍乱毒素B亚单位组成的新的口服疫苗已经大量人体试验证明安全有效,此外霍乱毒素B亚单位是很强的粘膜免疫原,当与无关抗原结合在一起口服时,也是一个很好的佐剂。为获得大量霍乱毒素B亚单位,采用DNA重组技术,将霍乱毒素B亚单位基因与阿拉伯糖操纵子的表达载体pMPM-A4Ω质粒进行重组,pMPM-A4Ω表达载体是由阿拉伯糖(L-ara)所调控,具有高拷贝表达的特点。我们成功地构建了重组质粒和工程菌菌株,对其     

霍乱毒素B亚基基因具有自己的启动子

本研究发现并证实霍乱毒素B亚基基因上游Xba Ⅰ～Cla Ⅰ限制性片段内存在具有启动子活性的序列;在该启动子作用下,霍乱毒素B亚基表达水平可达200mg/L,氯霉素乙酰基转移酶基因表达水平随培养条件不同在0.3～10mg/L之间,大肠杆菌β-半乳糖苷酶基因的表达量达4100U/ml。在该启动子的控制下霍乱毒素B亚基基因可以高效表达,该启动子的存在可能是由于霍乱毒素操纵子中霍乱毒素B亚基表达量是A亚基的6倍。     

乙肝PreS_2抗原决定簇和霍乱毒素B亚基基因的融合与表达

通过全化学法按大肠杆菌密码偏性合成了乙肝炎病毒（ＨＢＶ）前Ｓ２抗原（ＰｒｅＳ２）抗原决定簇基因,与霍乱毒素Ｂ亚基基因的３’端融合。重组质粒转化大肠杆菌后融合基因得到高效表达,表达量达３０μｇ／ｍＬ,表达产物９５％以上分泌到胞外。表达的融合蛋白能与神经节苷脂ＧＭ１结合,说明融合蛋白保持了霍乱毒素Ｂ亚基（ＣＴＢ）的基本高级结构和生物学功能;酶联免疫吸附实验证明融合蛋白具有ＣＴＢ和ＨＢＶＰｒｅＳ２的抗原性;应用亲和层析纯化后得到了电泳纯融合蛋白制品,为研究融合蛋白免疫原性并进一步构建基因工程肽苗奠定了基础。     

乙肝PreS2抗原决定簇和霍乱毒素B亚基基因的融合与表达

通过全化学法按大肠杆菌密码偏性合成了乙肝炎病毒前Ｓ２抗原抗原决定簇基因,与霍乱毒素Ｂ亚基基因的３＇端融合,重组质粒转化大肠杆菌后融合基因得到高效表达,表达量达３０μｇｍＬ,表达产物９５％以上分泌到胞外,表达的融合蛋白能与神经节苷脂ＧＭ１结合,说明融合蛋白保持了霍乱霉素Ｂ亚基的基本高级结构和生物学功能;酶联免疫吸附实验证明融合蛋白具有ＣＴＢ和ＨＢＶＰｒｅＳ２的抗原性;应用亲和层析纯化后得到了电泳纯融     

CTB与HCV抗原决定簇融合蛋白的抗原性及其在抗HCV ELISA试剂盒中的应用

系统研究了通过霍乱毒素B亚基与HCV的4个抗原决定簇进行基因融合所表达的12种融合蛋白中HCV抗原决定簇的反应原性,探索了以融合蛋白为抗原,进行抗-HCV检测的途径。结果表明,多数融合蛋白中HCV抗原决定簇均能与对应的HCV抗体结合。以融合蛋白95082为抗原研制的抗-HCV ELISA试剂检测122名献血员血清,结果与美国雅培公司抗-HCV ELISA试剂检测的结果完全一致,经药品生物制品检定所检定,其特异性、灵敏度、精密性及稳定性均达到国家卫生部抗-HCV ELISA试剂的暂行检定标准。     

霍乱毒素B亚单位与胰岛素B链融合基因的克隆及原核表达分析

构建了霍乱毒素B亚单位(choleratoxinBsubunit,CTB)与胰岛素(insulin)B链的融合基因CTB-INSB,将该融合基因克隆到大肠杆菌表达载体pET-30a(+)中,获得重组质粒pETCIB;并将该质粒转入大肠杆菌菌株BL21(DE3)中;重组菌株经IPTG诱导后的表达产物经15％SDS-PAGE分析表明可以表达融合蛋白,其分子量约为15.4kDa,且主要以包涵体形式存在,约占全菌蛋白的30％。含CTB-INSB重组蛋白的包涵体经变性和复性后,可在体外自组装成五聚体结构。Westernblotting分析结果显示CTB-INSB可分别被霍乱毒素的抗体和胰岛素的抗体识别,表明该蛋白具有霍乱毒素B亚单位与胰岛素的双重抗原性。同时GM1-ELISA分析结果表明CTB-INSB在体外可与神经节苷脂GM1(monosialoganglioside)特异结合,进一步证实了它能够形成类似CTB五聚体的高级结构,具有生物活性。     

霍乱毒素

霍乱毒素是一种很强的粘膜免疫佐剂,本介绍了霍乱毒素的结构、霍乱毒素毒性的分子机理及近年来在霍乱毒素佐剂活性方面的研究进展,并探讨了霍乱毒素佐剂活性的分子机理。     

The channel domain of colicin A is inhibited by its immunity protein through direct interaction in the Escherichia coli inner membrane.

A bacterial signal sequence was fused to the colicin A pore-forming domain: the exported pore-forming domain was highly cytotoxic. We thus introduced a cysteine-residue pair in the fusion protein which has been shown to form a disulfide bond in the natural colicin A pore-forming domain between alpha-helices 5 and 6. Formation of the disulfide bond prevented the cytotoxic activity of the fusion protein, presumably by preventing the membrane insertion of helices 5 and 6. However, the cytotoxicity of the disulfide-linked pore-forming domain was reactivated by adding dithiothreitol into the culture medium. We were then able to co-produce the immunity protein with the disulfide linked pore-forming domain, by using a co-immunoprecipitation procedure, in order to show that they interact. We showed both proteins to be co-localized in the Escherichia coli inner membrane and subsequently co-immunoprecipitated them. The interaction required a functional immunity protein. The immunity protein also interacted with a mutant form of the pore-forming domain carrying a mutation located in the voltage-gated region: this mutant was devoid of pore-forming activity but still inserted into the membrane. Our results indicate that the immunity protein interacts with the membrane-anchored channel domain; the interaction requires a functional membrane-inserted immunity protein but does not require the channel to be in the open state.     

Mode of action of LciA, the lactococcin A immunity protein

Monoclonal antibodies were raised against a fusion between the Escherichia coli maltose-binding protein and LciA, the immunity protein that protects Lactococcus lactis against the effects of the bacteriocin lactococcin A. One of the antibodies directed against the LciA moiety of the fusion protein was used to locate the immunity protein in the L. lactis producer cell. LciA was present in the cytosolic. the membrane-associated, and the membrane fractions in roughly equal amounts, irrespective of the production by the cells of lactococcin A. The monoclonal antibody specifically reacted with right-side-out vesicles obtained from a strain producing the immunity protein. It did not react with inside-out vesicles of the same strain, or with right-side-out vesicles obtained from a strain producing both LciA and lactococcin A. Also, externally added lactococcin A blocked the interaction between the antibody and right-side-out vesicles obtained from a strain producing only LciA. The epitope in LciA was localized between amino acid residues 60 and 80. As the epitope could be removed from right-side-out vesicles by proteinase K, it is located at the outside of the cell. The immunity protein contains a putative a-amphiphilic helix from residue 29 to 47. A model is proposed in which this helix is thought to traverse the membrane in such a way that the C-terminal part of the protein, containing the epitope, is on the outside of the cell. Vesicle-fusion studies together with leucine-uptake experiments suggest that the immunity protein interacts with the putative receptor for lactococcin A, thus preventing pore formation by the bacteriocin.     

Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo

Hsp70s are a family of ATP-dependent chaperones of relative molecular mass around 70 kDa. Immunization of mice with Hsp70 isolated from tumor tissues has been proved to elicit specific protective immunity against the original tumor challenge. In this work, we investigated whether Hsp70 can be used as vehicle to elicit immune response to its covalence-accompanying antigen. A recombinant protein expression vector was constructed that permitted the production of recombinant protein fusing tumor-associated antigen (eg, Mela) to the C terminus of Hsp70. We found that the Hsp70-Mela fusion protein can elicit strong cellular immune responses against murine tumor B16, which expresses protein Mela. The Hsp70 peptide-binding domain deletion mutant of the fusion protein was sufficient for inducing Mela-specific cytotoxic T lymphocyte but was not sufficient for engendering potent anti-tumor immunity against B16. We also found that host natural killer (NK) cells were stimulated in vivo by C-terminal domain of Hsp70. We thus presume that Hsp70 fusion proteins suppress tumor growth via at least 2 distinct pathways: one is covalence-accompanying antigen dependent; another is antigen independent. The C-terminal domain of Hsp70 seemed to be the crucial part in eliciting antigen-independent responses, including NK cell stimulation, against tumor challenges. Furthermore, we found that immunization with multiple Hsp70 fusion proteins resulted in a better anti-tumor effect.     

Topology and function of the integral membrane protein conferring immunity to colicin A

The topology of the integral membrane protein Cai (colicin A immunity protein), which is required to protect producing cells from the pore-forming colicin A, was analysed using fusions to alkaline phosphatase. The properties of these fusion proteins support the model for Cai topology previously proposed on theoretical grounds. The protein was found to contain four transmembrane sequences and its N- and C-terminal regions were found to be directed towards the cytoplasm. Oligonucleotide-directed mutagenesis and sequence comparisons between Cai, Cbi (colicin B immunity protein), and Cni (colicin N immunity protein) were carried out to determine the functional regions of Cai. The possible roles of the various regions of Cai in its protective function and in its topological organization are discussed.     

HBsAg/GM-CSF融合蛋白在毕赤酵母中的表达及其免疫原性研究

为探索一种提高乙肝病毒表面抗原免疫原性的新方法,用PCR和基因重组技术构建HBsAg与GM-CSF的融合基因,并在毕赤酵母中分泌表达HBsAg/GM-CSF(S-GM)融合蛋白。表达产物用SDS-PAGE检测,W estern b lot分析,离子交换柱纯化后免疫昆明鼠,ELISA检测免疫小鼠血清中抗HBsAg的抗体水平。结果显示S-GM融合蛋白在毕赤酵母中获得了表达,离子交换柱一步纯化即可得到纯度达90%以上的S-GM。W estern b lot分析S-GM可分别与抗HBsAg及抗GM-CSF的抗体特异结合。ELISA检测发现第一次免疫后4w出现抗HBsAg的抗体,加强免疫后融合蛋白组几乎全部阳转,且抗体水平较HBsAg组(P=0.009<0.05)及HBsAg和GM-CSF的混合物组(P=0.032<0.05)高。HBsAg/GM-CSF融合蛋白能够在毕赤酵母中表达,且可增强HBsAg的免疫原性,为提高乙肝疫苗的免疫效果提供了新的思路与方法。     

Characterization of the protein conferring immunity to the antimicrobial peptide carnobacteriocin B2 and expression of carnobacteriocins B2 and BM1.

Cloning of a 16-kb DNA fragment from the 61-kb plasmid of Carnobacterium piscicola LV17B into plasmidless C. piscicola LV17C restores the production of the plasmid-encoded carnobacteriocin B2 and the chromosomally-encoded carnobacteriocin BM1 and restores the immune phenotype. This fragment also has sufficient genetic information to allow the expression of carnobacteriocin B2 and its immunity in a heterologous host. The gene locus (cbiB2) responsible for immunity to carnobacteriocin B2 is located downstream of the structural gene for carnobacteriocin B2 and encodes a protein of 111 amino acids (CbiB2). CbiB2 was expressed in Escherichia coli as a fusion of the maltose-binding protein and CbiB2. The fusion protein was purified on an amylose column and cleaved with factor Xa, and pure CbiB2 was isolated by high-performance liquid chromatography. The N-terminal amino acid sequence and mass spectrometry (molecular weight [mean +/- standard error], 12,662.2 +/- 3.4) of the purified protein agree with the information deduced from the nucleotide sequence of cbiB2. Western blot (immunoblot) analysis indicates that the majority of the intracellular pool of this immunity protein is in the cytoplasm and that a smaller proportion is associated with the membrane. CbiB2 confers immunity to carnobacteriocin B2, but not to carnobacteriocin BM1, when it is expressed in homologous or heterologous hosts. No protective effect is observed for sensitive cells growing in the presence of the bacteriocin when the immunity protein is added to the medium. The purified immunity protein does not show significant binding to microtiter plates coated with carnobacteriocin B2 and is not able to inactivate the bacteriocin in solution.     

Colicin A Immunity Protein Interacts with the Hydrophobic Helical Hairpin of the Colicin A Channel Domain in the Escherichia coli Inner Membrane

The colicin A pore-forming domain (pfColA) was fused to a bacterial signal peptide (sp-pfColA). This was inserted into the Escherichia coli inner membrane in functional form and could be coimmunoprecipitated with epitope-tagged immunity protein (EpCai). We constructed a series of fusion proteins in which various numbers of sp-pfColA alpha-helices were fused to alkaline phosphatase (AP). We showed that a fusion protein made up of the hydrophobic alpha-helices 8 and 9 of sp-pfColA fused to AP was specifically coimmunoprecipitated with EpCai produced in the same cells. This is the first biochemical evidence that Cai recognizes and interacts with the colicin A hydrophobic helical hairpin.     

日本血吸虫新基因Sj-MA的克隆、表达及保护性免疫

为发现新基因 ,寻找日本血吸虫病新疫苗候选分子 ,采用Sj雄虫免疫血清筛选Sj成虫cDNA文库。经测序发现新基因Sj MA含有一个完整的阅读框 ,推测其由 2 4 9个氨基酸组成 ,编码分子量为 2 8.8kD的可溶性蛋白质 ,并带有多个能被磷酸化激活的位点 ,提示其可能为一重要的信息传递分子。将Sj MA的cDNA亚克隆至原核表达载体pGEX 5X ,获得Sj MA原核表达的重组体rSj MA/GST ,并在E .coli中高效表达为谷胱甘肽S 转移酶 (GST)融合蛋白 ,分子量为 5 4 .8kD ,Western印迹显示融合蛋白质能被抗雄虫和抗GST血清识别。融合蛋白质免疫小鼠可诱导 34.2 9%的减虫率 ,与对照组有显著性差异 (P <0 .0 0 1 )。表明新基因Sj MA表达的蛋白质能诱导小鼠的抗日本血吸虫的保护性免疫 ,提示其作为日本血吸虫疫苗候选分子的潜在价值     

A novel strategy for converting recombinant viral protein into high immunogenic antigen.

Interleukin 2 (IL-2) is a lymphokine promoting immune response and therefore has been investigated as an immunological adjuvant. In order to enhance the immunogenicity of recombinant viral protein, herpes simplex virus type 1 (HSV-1) glycoprotein D (gD), we genetically created a fusion protein consisting of gD and human IL-2. The fusion protein, without any other adjuvants, induced high antibody responses and cell-mediated immunity to HSV-1 in mice. Mice immunized with the fusion protein were protected against HSV-1 infection. The results indicate that IL-2-fusing can provide a means for converting a weak immunogenic protein into a high immunogenic antigen, and the strategy would be widely applicable to the other antigens for pathogens.     

人apoA-I分泌型表达调控细胞模型构建

分别从pMD18-T质粒和人基因组DNA扩增出人apoA-I CDS区序列和apoA-I启动子(702bp片段),与pEGFP-N1重组,构成受apoA-I启动子调控的pEGFP-N1质粒和融合蛋白表达质粒,分别转染人肝癌HepG2细胞,以绿色荧光为标志筛选稳定转染系列克隆。用RT-PCR、荧光显微镜、免疫荧光术等鉴定其中一个克隆融合蛋白的表达;分别以胰岛素和葡萄糖刺激物鉴定该克隆的外源apoA-I启动子调控。结果表明:人apoA-I分泌型表达调控肝细胞模型初步建成。